Lundbeck CDM has decades of experience in development and production services related to APIs and custom manufacturing services.

Reset all filters
01 14Abilify
02 1Abilify Asimtufii
03 1Abilify LAI Franchise
04 16Abilify Maintena
05 1Abilify Maintena/Abilify Asimtufii
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 369
2019 Revenue in Millions : 319
Growth (%) : 16
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 369
2020 Revenue in Millions : 363
Growth (%) : 7
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 427
2021 Revenue in Millions : 369
Growth (%) : 16
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 459
2022 Revenue in Millions : 427
Growth (%) : 8
Main Therapeutic Indication : Neurology
Currency : USD
2024 Revenue in Millions : 486
2023 Revenue in Millions : 459
Growth (%) : 6
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 31
2014 Revenue in Millions : 100
Growth (%) : 223%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 226
2016 Revenue in Millions : 189
Growth (%) : 19
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 239
2017 Revenue in Millions : 200
Growth (%) : 20%
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 294
2018 Revenue in Millions : 239
Growth (%) : 23
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 1,101
2019 Revenue in Millions : 966
Growth (%) : 14




